within Pharmacolibrary.Drugs.ATC.J;

model J07CA12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 0.5 / 1000000,
    adminCount     = 1,
    Vd             = 0,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>This is a combination vaccine used to protect against five serious diseases: diphtheria, pertussis (whooping cough), poliomyelitis, tetanus, and hepatitis B. It is administered primarily to infants and young children as a part of routine immunization schedules. The vaccine is approved and widely used in pediatric practice worldwide.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies or compartmental PK models are available for the pentavalent diphtheria-pertussis-poliomyelitis-tetanus-hepatitis B combination vaccine. The vaccine is typically given as an intramuscular injection in infants and young children; classical pharmacokinetic parameters (such as systemic absorption rates, central volume of distribution, clearance) are not generally relevant or reported for vaccines.</p><h4>References</h4><ol><li><p>Zhu, Q, et al., &amp; Suzich, JA (2017). A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. <i>Science translational medicine</i> 9(388) –. DOI:<a href=&quot;https://doi.org/10.1126/scitranslmed.aaj1928&quot;>10.1126/scitranslmed.aaj1928</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28469033/&quot;>https://pubmed.ncbi.nlm.nih.gov/28469033</a></p></li><li><p>Neupane, N, et al., &amp; Dhakal, A (2024). Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer. <i>Cancers</i> 16(3) –. DOI:<a href=&quot;https://doi.org/10.3390/cancers16030619&quot;>10.3390/cancers16030619</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38339371/&quot;>https://pubmed.ncbi.nlm.nih.gov/38339371</a></p></li><li><p>Thakkar, K, &amp; Billa, G (2015). Treatment of vitamin B12 deficiency-methylcobalamine? Cyancobalamine? Hydroxocobalamin?-clearing the confusion. <i>European journal of clinical nutrition</i> 69(1) 1–2. DOI:<a href=&quot;https://doi.org/10.1038/ejcn.2014.165&quot;>10.1038/ejcn.2014.165</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25117994/&quot;>https://pubmed.ncbi.nlm.nih.gov/25117994</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J07CA12;
